| Hans-Günter Meyer-Thompson | Hepatitiden
Navigating the Hep C Treatment and Cancer Risk Minefield
AMSTERDAM — Contradictory findings are driving disagreement over whether patients cured of hepatitis C after treatment with direct-acting antivirals should be monitored for hepatocellular carcinoma.
A flashpoint in the controversy was a Spanish study that revealed a 28% rate of radiologic tumor recurrence in 103 people with a history of liver cancer who were treated with direct-acting antivirals (J Hepatol. 2016;65:719-726). In that study, the investigators noted that the "high rate of cancer recurrence" after patients with a history of hepatocellular carcinoma were treated with direct-acting antivirals should prompt larger trials. (Medscape Coverage from the International Liver Congress (ILC) 2017, 02.06.2017)